Delivery Order SPE2DB22D3301-SPE2DB25FX5SJ
Award Date
11/18/24
Potential Completion Date
11/19/24
Potential Value
$99K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,821.98 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product used in medical treatment. The contract has an ultimate completion date of October 17, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,365.64 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical commodity used for healthcare purposes. The contract has an ultimate completion date of February 5, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $21,204.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medication used in the treatment of cystic fibrosis. This is a firm fixed-price delivery order contract with a completion date of September 22, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a ceiling value of $10,472.72. The contract is a Firm Fixed Price Delivery Order, with a period of performance through January 21, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,988.66 firm fixed-price delivery order is for Pulmozyme 1 mg/mL ampules (2.5 mL) and has a completion date of November 21, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a broad range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The $6,929.36 firm fixed-price delivery order has an ultimate completion date of April 20, 2023. The contract is not designated as a set-aside award. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,139.40, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract type is a Delivery Order, with a Firm Fixed Price pricing structure, and an ultimate completion date of January 3, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a...
This federal contract award, with ID SPE2DB20D1100|SPE2DB23FD8F8, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $63,169.88 firm fixed-price delivery order is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, to support federal healthcare programs. The contract has an ultimate completion date of September 26, 2023. AmerisourceBergen holds a significant Indefinite...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,543.24 firm fixed-price delivery order is for the provision of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of November 20, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award, identified as SPE2DB20D3101|SPE2DB25FRAL2, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $5,167.20 firm fixed-price delivery order is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product, with a completion date of January 31, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...